PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the apperwork Registron Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control								
MADEAM					Complete if Known			
Substitute for form 1449/PTO					Application Number	09/757,673		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Filling Date	January 10, 2001		
					First Named Inventor	J. Wilson et al		
					Group Art Unit	1632		
(Use as many sheets as necessary)			necessary)	Examiner Name	Ram R. Shukla			
Sheet	1	of		1	Attorney Docket Number	GNVPN.019B1USA		

	NONPATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²			
OV	BBS	WISTUBA ET AL, Subcellular Compartmentalization of Adeno-Associated Virus Type 2 Assembly, Journal of Virology, Vol. 71, No. 2, pp. 1341-1352, (February 1997)				
g~	BBT	WOBUS ET AL, Monoclonal Antibodies against the Adeno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2-Cell Interaction and Neutralization of AAV-2 Infection, Vol. 74, No. 19, pp. 9281-9293, (October 2000)				

Examiner Signature SAN A LAL	Date Considered U/\(\mathcal{k}\)

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

NO	N 1 0 2		the Paperwo	rk Reduction Act of 1995, no pe	ersons are required to respond to a G	PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE collection of information unless it contains a valid OMB control number.	
(SI		.8./			Complete If Known		
Y	Substitute Romorm 1449/PTO				Application Number	09/757,673	
	INF	ORMAT	ΓΙΟΝ	DISCLOSURE	Filing Date	January 10, 2001	
ł	STA	ATEMEI	NT BY	APPLICANT	First Named Inventor	James M. Wilson et al	
(Use as many sheets as necessary)					Group Art Unit	1632	
				•	Examiner Name	R. Shukla	
┢	Choot	1	Of	72	Attorney Docket Number	GNVPN 019B1USA	

	<u>-</u>		U.S. PATENT DOCUM	ENTS	
Examiner	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials*	No.1	Number-Kind Code ^{2(if known)}	MM-DD-TTTT	Cited Document	Figures Appear
BV	BBU	US-6,093,534	07-25-2000	Shimada et al	
	<u> </u>				
	 				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ -Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	16	
		Coding Code Name Code (Manual)					
						Γ	
						T	
						1	
						1	

	Date Considered W/\(\(\)\(\)
Signature (1) And (2) C	Considered 111173

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

OIPE	\
MOV 1 0 2004	ດ ເມື່ອ Under the Paperwork Reduction Act of 1995,
Substituted IRADEMA	f form 1449/PTO

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	/			Complete if Known			
Substitute of	r form 1449/	PIO		Application Number	09/757,673		
INFO	RMATI	ON E	DISCLOSURE	Filing Date	January 10, 2001		
STATEMENT BY APPLICANT				First Named Inventor	James M. Wilson et al		
				Group Art Unit	1632		
(Use	e as many si	neets as	necessary)	Examiner Name	R. Shukla		
Sheet	2	of	2	Attorney Docket Number	GNVPN.019B1USA		

NONPATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²		
Br	BBV	JOHNSON ET AL, RAAV Vectors as Novel HIV-1 Vaccine Candidates: Immunogenicity in Non-Human Primates, Gene Therapy Applications (Session 2C), Xth Parvovirus Workshop, St. Petersburg, FL, September 8-12, 2004			
0r	BBW	ZHI ET AL, Increased Antigen-Specific Humoral Response by Adenoviral Vector Prime and Adeno-Associated Viral Vector Boost, 7 th Annual Meeting of the American Society for Gene Therapy, June 2-6, 2004, Minneapolis, Minnesota, e-publ. May 3, 2004			
	 				
	ļ				
	-		<u> </u>		
· · · · · · · · · · · · · · · · · · ·					
		· ·			
	-		 		

	<u> </u>		
Examiner 0		Date	III feet
Signature Shank	hoton	Considered	4/1/0)

Signature

| Signature | 13 | Mark | Considered | Conside

Substitute for Form 1449A/PTO		Complete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	09/757,673
PE (use as many sheets as necessary)	Filing Date	January 10, 2001 🛱 🖟 🔿
O' CI	First Named Inventor	James M. Wilson et 🕮 🖰 🔟
MAR 1 6 2001	Group Art Unit	1632 600 79.5 M
MAR 1 6 2001 E	Examiner Name	1 Martin P. Shighle U
Sheet 7 of 11	Attorney Docket Number	GNVPN.019B1USA

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiners Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
PR9	AZ	R. SAMULSKI et al, "Targeted Integration of Adeno-Associated Virus (AAV) into Human Chromosome 19", EMBO J., 10(12):3941-3950 (1991) [Samulski I]	
	AAR	R. KOTIN, "Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy", Human Gene Therapy, 5:793-801 (1994) [Kotin I]	
	AAS	R. KOTIN et al, "Site-Specific Integration by Adeno-Associated Virus", Proc. Natl. Acad. Sci. USA, 87:2211-2215 (March, 1990) [Kotin II]	
	AAT	K. FISHER et al, "Transduction with Recombinant Adeno-Associated Virus for Gene Therapy is Limited by Leading-Strand Synthesis", J. Virol., 70(1):520-532 (January, 1996) [Fisher II]	
	AAU	C. HODGSON, "Advances in Vector Systems for Gene Therapy", Exp. Opin. Ther. Patents, 5(5):459-468 (1995)	
	AAV	R. SAMULSKI et al, "Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration does not Require Viral Gene Expression", J. Virol., 63(9):3822-3828 (September, 1989) [Samulski II]	
12725	AAW	M. WEITZMAN et al, "Recruitment of Wild-Type and Recombinant Adeno- Associated Virus into Adenovirus Replication Centers", J. Virol., 70(3):1845-1854 (March, 1996)	
BW	AAX	S. GOODMAN et al, "Recombinant Adeno-Associated Virus-Mediated Gene Transfer into Hematopoietic Progenitor Cells", Blood, 84(5):1492-1500 (September, 1994)	

Examiner Signature Date Considered 11 1970)

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.